T. Sidoni

发表

Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption.

C. Ficorella, K. Cannita, A. Parisi, 2021, Breast disease.

From adjuvant to preventive breast cancer treatment: bridging the gap over troubled waters.

E. Ricevuto, C. Ficorella, Z. C. di Rocco, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status

C. Ficorella, K. Cannita, A. Tessitore, 2022, Cancers.

Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study.

M. Tiseo, C. Ficorella, K. Cannita, 2018, Immunotherapy.

Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families

I. Screpanti, G. Giannini, E. Ricevuto, 2006, Breast Cancer Research and Treatment.

Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes

C. Ficorella, K. Cannita, A. Tessitore, 2020, Journal of personalized medicine.

First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience

C. Ficorella, K. Cannita, A. Parisi, 2019, Clinical and Translational Oncology.

Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama.

R. Bisegna, E. Ricevuto, P. Marchetti, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software

I. Screpanti, G. Giannini, E. Ricevuto, 2006, European Journal of Human Genetics.

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis

E. Ricevuto, C. Ficorella, K. Cannita, 2017, Oncotarget.

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice

C. Ficorella, K. Cannita, A. Parisi, 2018, Oncology letters.

Identification and Characterization of BRCA 1 and BRCA 2 Founder Mutations

S. Iacobelli, G. Giannini, F. Baudi, 2012 .

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations

E. Ricevuto, C. Ficorella, K. Cannita, 2018, Oncotarget.

Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer.

E. Ricevuto, C. Ficorella, K. Cannita, 2016, Bone.

Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families

I. Screpanti, G. Giannini, E. Ricevuto, 2007, Breast Cancer Research and Treatment.

BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.

A Gulino, I. Screpanti, G. Giannini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study

C. Ficorella, K. Cannita, A. Parisi, 2020, Journal of Gastrointestinal Cancer.